The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation

The recruitment status of this study is unknown because the information has not been verified recently.

Verified June 2005 by National Taiwan University Hospital. Recruitment status was Recruiting

First Received on September 12, 2005. Last Updated on November 29, 2005 History of Changes

Sponsor:	National Taiwan University Hospital
Information provided by:	National Taiwan University Hospital
ClinicalTrials.gov Identifier:	NCT00173199

Purpose

In order to increase our understanding about the pathogenic mechanism and the strategy of treatment in the subtypes of Guillain Barré syndrome, we will check the temporal changes of cytokines with different biological activities in serum and cerebrospinal fluid (CSF), check the titer of various anti-ganglioside antibodies, perform skin biopsy and correlate these data with the clinical findings such as severity and prognosis

Condition
Guillain Barré Syndrome

Study Type:	Observational
Study Design:	Observational Model: Defined Population Primary Purpose: Screening Time Perspective: Cross-Sectional Time Perspective: Prospective
Official Title:	The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation

Resource links provided by NLM:

Genetics Home Reference related topics: Guillain-Barré syndrome

MedlinePlus related topics: Guillain-Barre Syndrome

U.S. FDA Resources

Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment:	150
Study Start Date:	June 2005

Show Detailed Description

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Progressive weakness of both legs and arms; areflexia; cranial nerve involvement (such as facial palsies); progression over days to 4 wks; recovery beginning 2-4 wks after progression ceases; elevated cerebrospinal fluid protein with <10 cells/µl; electrodiagnostic features of nerve conduction slowing or block.

Exclusion criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00173199

Contacts

Contact: Sung-Tsang Hsieh, PhD

886-2-23123456 ext 8182

sthsieh@ha.mc.ntu.edu.tw

Locations

Taiwan
Department of Anatomy and Cell Biology, National Taiwan University College of Medicine	Recruiting
Taipei, Taiwan
Contact: Sung-Tsang Hsieh, PhD 886-2-23123456 ext 8182 sthsieh@ha.mc.ntu.edu.tw

Sponsors and Collaborators

National Taiwan University Hospital

Investigators

Study Director:

Sung-Tsang Hsieh, PhD

Department of Anatomy and Cell Biology, National Taiwan University College of Medicine; Department of Neurology, National Taiwan University Hospital

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00173199 History of Changes
Other Study ID Numbers:	9461700526
Study First Received:	September 12, 2005
Last Updated:	November 29, 2005
Health Authority:	Taiwan: Department of Health

Additional relevant MeSH terms:

Guillain-Barre Syndrome
Polyradiculoneuropathy
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases

Peripheral Nervous System Diseases
Neuromuscular Diseases
Polyneuropathies
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on February 09, 2012